NCT05891171View on ClinicalTrials.gov

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced CancerAdvanced MalignanciesBladder CancerCervical CancerEsophageal CancerGastric CancerGastroesophageal-junction Cancer (GEJ)Head and Neck Squamous Cell Carcinoma (HNSCC)Non-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)
Interventions
DRUG

AB598

Administered as specified in the treatment arm

DRUG

Zimberelimab

Administered as specified in the treatment arm

DRUG

Fluorouracil

Administered as specified in the treatment arm

DRUG

Leucovorin

Administered as specified in the treatment arm

DRUG

Oxaliplatin

Administered as specified in the treatment arm

Trial Locations (15)

22031

Next Oncology Virginia, Fairfax

32024

Lake City Cancer Care, LLC., Lake City

32224

Mayo Clinic Florida, Jacksonville

44106

University Hospitals Cleveland Medical Center, Cleveland

44718

Gabrail Cancer Center (GCC) Canton Facility, Canton

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic Rochester, Rochester

60521

Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale

75039

Next Oncology Dallas, Irving

85054

Mayo Clinic Arizona, Phoenix

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Unknown

Adelaide Cancer Research, Adelaide

Queen Elizabeth Hospital, Adelaide

National Cheng Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Arcus Biosciences, Inc.

INDUSTRY